The blend is the most-searched form of either peptide and the one with the least evidence behind it: no trial has ever given CJC-1295 and ipamorelin together. What exists is a set of vendor and clinic figures for each component and an arithmetic problem that trips readers more often than any other on this site, the meaning of the number on a blend vial. This page reports the figures with their dates and then works the blend arithmetic for the 5 mg and 10 mg vials the site's calculator uses.
CJC-1295 is a growth-hormone-releasing-hormone analogue and ipamorelin is a ghrelin-receptor agonist; the pairing is sold because the two act on growth-hormone release through different receptors. Medibact's CJC-1295 guide and Medibact's Ipamorelin guide cover each molecule and its evidence, and this site's CJC-1295 and Ipamorelin combination article covers why they are paired; this page stays with figures. The CJC-1295 page and the ipamorelin page carry each component's full record, the dosage hub lists every compound, and Peptifact's CJC-1295 ipamorelin page grades the same sources from a journalist's angle.
What the sources state
| Source | Kind | Figure | Date read |
|---|---|---|---|
| ClinicalTrials.gov searches, "CJC-1295" and "ipamorelin" | Registry | One CJC-1295 record (DAC alone, terminated); three ipamorelin records (all intravenous); no study of the combination | 2026-09-18 |
| Teichman et al., JCEM 2006; Ionescu and Frohman, JCEM 2006 | Trial publications (CJC-1295 with DAC) | Single subcutaneous doses of 30 to 90 mcg/kg; weekly or biweekly at 30 to 60 mcg/kg; half-life 6 to 8 days | 2026-09-18 |
| Gobburu et al., 1999; Beck et al., 2014 | Trial publications (ipamorelin) | Intravenous infusions of about 3 to 100 mcg/kg once; 0.03 mg/kg intravenously twice daily for 7 days | 2026-09-18 |
| Vendor and clinic page A | Commonly cited | 100 to 300 mcg of CJC-1295 (no DAC) with 100 to 300 mcg of ipamorelin per injection; 100 mcg of each once or twice daily to start; 200 to 300 mcg of each 2 to 3 times daily; 10 mg blend vial at 2 mL (5 mg/mL), 300 mcg = 6 units; cycles of 8 to 12 weeks | 2026-09-18 |
| Vendor and clinic page B | Commonly cited | 300 to 500 mcg of total blend per injection, 2 to 3 times daily; a beginner pattern of 300 mcg once daily before bed; 10 mg vial at 2 mL; 6 units = 300 mcg, 10 units = 500 mcg | 2026-09-18 |
| This site's calculator note | Site reference | A 10 mg blend vial generally holds 10 mg in total, often 5 mg and 5 mg; the split is not standardised | 2026-09-18 |
Two things follow. The component trial figures are for different molecules and routes than the blend contains, DAC rather than no-DAC for the CJC-1295 and intravenous rather than subcutaneous for the ipamorelin, so they do not underwrite the blend figures even indirectly. And the two vendor pages agree with each other because they describe the same convention: 100 to 300 mcg of each, which as total blend is 200 to 600 mcg.
The number on a blend vial
The labelled milligrams on a blend vial are the combined peptide mass. A vial marked 10 mg usually holds 10 mg of peptide in total, and a common fill is 5 mg of each, but a 6:4 or 7:3 fill is also a 10 mg vial. The calculator therefore returns the concentration of the blend as a whole. To get a per-peptide figure the split must be known, and the only place it is stated is the vial's own documentation. A unit figure quoted from someone else's vial does not transfer: a different total, a different split or a different water volume each changes the answer on its own.
Units per draw at each blend-vial size
Research-market blends are supplied as 5 mg and 10 mg vials of total peptide. The first table takes each at 1, 2 and 3 mL, states the blend concentration, and converts 200, 300, 400, 500 and 600 mcg of total blend (100 to 300 mcg of each at a 1:1 fill) into U-100 syringe units, where 100 units is 1 mL (MedlinePlus, read 2026-09-18); the site's insulin syringe units page covers the syringe reading itself.
| Vial (total) | Water added | Blend concentration | 200 mcg | 300 mcg | 400 mcg | 500 mcg | 600 mcg |
|---|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 4 | 6 | 8 | 10 | 12 |
| 5 mg | 2 mL | 2.5 mg/mL | 8 | 12 | 16 | 20 | 24 |
| 5 mg | 3 mL | 1.67 mg/mL | 12 | 18 | 24 | 30 | 36 |
| 10 mg | 1 mL | 10 mg/mL | 2 | 3 | 4 | 5 | 6 |
| 10 mg | 2 mL | 5 mg/mL | 4 | 6 | 8 | 10 | 12 |
| 10 mg | 3 mL | 3.33 mg/mL | 6 | 9 | 12 | 15 | 18 |
The second table reads the other way: what a fixed 10-unit draw (0.1 mL) delivers at each concentration, in total blend and per peptide at a stated 5 mg/5 mg split. A vial with a different split delivers the same total and a different division.
| Vial (total) | Water added | Blend concentration | 10 units delivers | Each peptide at 1:1 |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 500 mcg | 250 mcg |
| 5 mg | 2 mL | 2.5 mg/mL | 250 mcg | 125 mcg |
| 5 mg | 3 mL | 1.67 mg/mL | 167 mcg | 83 mcg |
| 10 mg | 1 mL | 10 mg/mL | 1,000 mcg | 500 mcg |
| 10 mg | 2 mL | 5 mg/mL | 500 mcg | 250 mcg |
| 10 mg | 3 mL | 3.33 mg/mL | 333 mcg | 167 mcg |
A 10 mg vial holds fifty 200 mcg blend draws and a 5 mg vial twenty-five, whichever water volume is used. The CJC-1295 + Ipamorelin calculator works any combination for a single blended vial; the blend calculator handles an uneven split or two separate vials drawn into one syringe, and the site's blend reconstitution page covers water volumes per vial and the mixing steps as references describe them.
One vial means the ratio is locked
When both peptides share a vial, every draw delivers them in the fill ratio, and changing the volume drawn scales both together. A 1:1 vial cannot deliver 200 mcg of ipamorelin with 100 mcg of CJC-1295; only separate vials allow the two amounts to move independently, at the cost of two draws and two calculations. That is what the arithmetic permits and forbids; it is not a view on which arrangement anyone should use.
What the figures omit
The vendor figures carry a route, a frequency, timing rules (before bed, fasted) and a cycle; they carry no population, no endpoint and no trial. They also carry no form: none of the pages opened says whether the CJC-1295 in the vial is the no-DAC form (the usual case) or the DAC form (a different molecule with a week-long half-life), and this site's calculator note makes the same point. The component trials carry populations and routes that the blend does not share. Nothing in the record says what the two peptides do to each other's release in people, because no study has measured it.
What this page does not do
This page reports figures with their sources and dates and works the blend-vial arithmetic at the site's vial sizes. It does not recommend a dose, a split, a frequency or a course for anyone, does not say whether the combination works, and does not turn the vendor convention into advice. The mixing steps and the storage of a mixed vial are the store's topics: how to reconstitute peptides and how to store peptides on medibact.com.
Sources and dates
Opened 2026-09-18: the ClinicalTrials.gov v2 API for "CJC-1295" (one record) and "ipamorelin" (three records); PubMed through the NCBI E-utilities for the abstracts of PMIDs 16352683, 17018654, 10496658 and the 2014 ileus trial; two vendor and clinic pages carrying dated blend figures and reconstitution arithmetic (three further pages were blocked or timed out and were not read); this site's calculator note for the blend; and MedlinePlus for the U-100 definition. Corrections go to the contact page.